Biontech SE (BNTX)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 33% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- QualityRevenue shrinking (-12% y/y)-11
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 Dominant catalyst is product/pipeline news, driven by clinical data updates and peer validation in the cancer vaccine space. Continuation probability is moderate, as positive headlines can sustain momentum but are subject to data-readout volatility. Informational only — not financial advice.
- Why Is Arbutus Biopharma Stock Gaining Friday?Benzinga · 2026-08-21
- Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine AdvanceSeekingAlpha · 2026-08-20
- BioNTech Will Present New Data From Its Development Program in Lung Cancer Treatment at the IASLC 2026 World Conference on Lung Cancer In September; Data Highlights Progress Across Pumitamig (BNT327/BMS986545) and Gotistobart (BNT316/ONC-392), As Well As BioNTech’s mRNA-Based Immunotherapy ApproacheBenzinga · 2026-08-20
- Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending TonightBenzinga · 2026-08-19
- Merck Just Raised the Stakes for Pfizer's Cancer Vaccine AmbitionsBenzinga · 2026-08-19
Any AI summary is an interpretation of public news, not advice or a price target.